Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors

HIV Clinical Trials

Volumn 4, Issue 3, 2003, Pages 164-169

  Narayan, Shanil ^a   Hawley, Nanci ^a   Giguère, Pierre ^a   Badley, Andrew D ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

CD4 T cell response; Fibrates; HMG CoA reductase inhibitors; Hyperlipidemia

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; CD4 ANTIGEN; CD8 ANTIGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATTENUATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; T LYMPHOCYTE; TIME; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; RETROSPECTIVE STUDIES;

EID: 0038676897     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/B05E-TFVN-UJ8L-MFHJ     Document Type: Article

References (23)

1. Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. Blood. 2000;96(9):2951-2964.
2. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13(10):F63-70.
3. Duong M, Cottin Y, Piroth L, et al. Exercise stress testing for detection of silent myocardial ischemia in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2002;34(4):523-528.
4. Carcelain G, Debre P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol. 2001;13(4):483-488.
5. Giovannetti A, Pierdominici M, Mazzetta F, et al. T-cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T-cell receptor repertoire and anti-HIV T-lymphocyte activity. Clin Exp Immunol. 2001;124(1):21-31.
6. Lempicki RA, Kovacs JA, Baseler MW, et al. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T-cell turnover in HIV-infected patients. Proc Natl Acad Sci USA. 2000;97(25):13778-13783.
7. Ogata Y, Takahashi M, Takeuchi K, et al. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. J Cardiovasc Pharmacol. 2002;40(6):907-915.
8. Morikawa S, Takabe W, Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb. 2002;9(4):178-183.
9. Undas A, Brozek J, Musial J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab. 2002;48(5-6):287-296.
10. Hattori Y, Nakanishi N, Kasai K. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc Res. 2002;54(3):649-658.
11. Bickel C, Rupprecht HJ, Blankenberg S, et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol. 2002;82(1):25-31.
12. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44(12):2870-2878.
13. Murphy RT, Foley JB, Mulvihill N, Crean P, Walsh MJ. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol. 2001;87(4):446-448, A6.
14. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7(6):687-692.
15. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999;13(2):213-224.
16. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399-1402.
17. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47(4):648-657.
18. Montero MT, Hernandez O, Suarez Y, et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis. 2000;153(2):303-313.
19. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol. 2000;86(2):83-91.
20. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999;5(8):2223-2229.
21. Palinski W. Immunomodulation: a new role for statins? Nat Med. 2000;6(12):1311-1312.
22. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353(9157):983-984.
23. Hassan AT, Dai Z, Konieczny BT, et al. Regulation of alloantigen-mediated T-cell proliferation by endogenous interferon-gamma: implications for long-term allograft acceptance. Transplantation. 1999;68(1):124-129.